The Real Disadvantages of Wegovy — and What the Evidence Actually Shows

The biggest misconception: side effects are rare and mild

Many people come to their first consultation having heard that nausea settles quickly and is only a minor inconvenience. That framing undersells what some patients experience. In the STEP 1 trial, published in the New England Journal of Medicine, gastrointestinal events were by far the most common reason participants stopped treatment. Nausea affected the majority of those on semaglutide at some point during the study. Vomiting, diarrhoea, constipation and persistent reflux were also reported significantly more often than in the placebo group.

The good news (and it matters) is that these effects are usually most intense in the first few weeks after starting a new dose, then ease. Eating smaller portions, avoiding fatty or strongly spiced food, and not lying down straight after meals all help. Still, for a proportion of people the nausea is genuinely disruptive, and a smaller group find it severe enough to pause or discontinue treatment. Knowing this in advance, rather than being surprised by it, tends to help. The NHS semaglutide medicines page covers common and less common side effects in plain language and is worth reading before you begin.

Injection-site reactions (redness, bruising, mild tenderness) are also listed among common effects, though these are generally less troublesome than the GI picture. Fatigue and headache in the early weeks appear often enough to be worth flagging to anyone with a demanding job or caring responsibilities.

The slow titration: Wegovy's results take longer than the headlines suggest

The standard Wegovy pathway moves through five dose levels (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg) spending roughly four weeks at each. That means most people are at the maintenance dose only from around month five onwards. A higher 7.2 mg dose was approved by the MHRA in April 2026, but the titration to reach it takes even longer. If you want to understand what the stages of Wegovy involve and how each dose period differs from the last, that detail is worth reading before you start.

This is not a flaw in the drug's design. The staggered increase exists to give the body time to adjust and to reduce the severity of those GI side effects. But it does mean that anyone expecting dramatic results within the first month is likely to be disappointed. Weight loss during the early doses is often modest. The clinical trial figures (around 15% average body-weight reduction over 68 weeks at 2.4 mg) reflect what happens across the full treatment period, not a quick sprint at the start.

That timeline also has a practical consequence for cost. You're paying for several months of treatment before reaching the dose at which most of the clinical benefit occurs. The Wegovy overview page goes into more detail on what to expect at each stage.

Supply, NHS access and what Wegovy's limitations mean for cost

Wegovy has faced repeated shortages since its UK launch. Demand outpaced supply, and while availability has improved, it remains uneven. Specific dose strengths can still be out of stock at a given time, an inconvenience that carries clinical weight, because an unplanned gap in treatment or an unintended regression to a lower dose can disrupt progress. Our guide to Wegovy shortages explains what to do if you encounter this.

NHS access is tightly restricted. Under NICE guidance TA875, Wegovy on the NHS is available only through specialist weight management services, for a maximum of two years, and for adults meeting specific BMI and comorbidity thresholds. Waiting lists at many specialist services run to months or longer. That's the reality for most people who ask their GP about it today.

Private prescriptions sidestep those waiting lists, but the monthly outlay is significant. A single transparent price that covers clinical review, prescription and delivery is more honest than headline-per-pen figures that exclude consultation or aftercare fees. If you're comparing costs across providers, our treatment page sets out exactly what's included at nume, and it's worth understanding what other providers may charge separately before assuming a lower headline is actually better value.

Less-discussed disadvantages: pancreatitis risk, contraception interactions and long-term use

A few disadvantages sit outside the usual side-effect list and deserve a direct mention. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonists (including semaglutide) specifically highlighting acute pancreatitis as an infrequent but serious risk. Severe or persistent stomach pain that spreads towards the back, with or without vomiting, needs prompt medical attention rather than a wait-and-see approach. This is the kind of detail a prescriber reviews your history against before treatment starts.

Women taking oral contraceptives should be aware that GLP-1 medicines can slow gastric emptying in a way that affects how medicines are absorbed. For tirzepatide there is specific guidance about adding a non-oral method for a period after dose changes; the picture for semaglutide is less clear-cut, but it's worth discussing with your prescriber or GP, particularly around the range of less-obvious physical changes people notice during treatment. Our Wegovy images page shows what the pen, injection sites and dose markings look like, which can also help you feel more prepared before your first injection. The NHS England guidance on weight management injections includes advice on contraception and other interactions worth reading before you start.

Long-term use is another open question. The two-year cap in the NICE NHS recommendation reflects the evidence base available at the time of appraisal rather than a known harm at that duration. Weight tends to return if treatment stops, which raises the practical question of sustainability. That's not a reason to avoid treatment, but it is a disadvantage worth planning around with whoever is prescribing for you.